	US 12,071,457 B2
	Disease treatment drug based on mesenchymal-stem-cell mobilization
Katsuto Tamai, Osaka (JP); Takashi Shimbo, Osaka (JP); and Takehiko Yamazaki, Osaka (JP)
Assigned to STEMRIM INC., Osaka (JP); and OSAKA UNIVERSITY, Osaka (JP)
Appl. No. 17/282,872
Filed by StemRIM Inc., Osaka (JP); and OSAKA UNIVERSITY, Osaka (JP)
PCT Filed Oct. 4, 2019, PCT No. PCT/JP2019/039231 § 371(c)(1), (2) Date Apr. 5, 2021, PCT Pub. No. WO2020/071519, PCT Pub. Date Apr. 9, 2020.
Claims priority of application No. 2018-190089 (JP), filed on Oct. 5, 2018.
Prior Publication US 2021/0347839 A1, Nov. 11, 2021
Int. Cl. C07K 14/47 (2006.01); A61K 38/00 (2006.01); A61P 1/00 (2006.01); A61P 17/06 (2006.01); A61P 37/06 (2006.01)

CPC C07K 14/4713 (2013.01) [A61P 1/00 (2018.01); A61P 17/06 (2018.01); A61P 37/06 (2018.01); A61K 38/00 (2013.01); C07K 2319/09 (2013.01)]

5 Claims

1. A method for mobilizing mesenchymal stem cells to peripheral blood, comprising administering to a subject an effective amount of a peptide consisting of the amino acid sequence that is at least 95% identical to the amino acid sequence selected from the group consisting of SEQ ID NOs: 35 to 56, wherein the peptide consists of a fragment of a nuclear protein and has activity of mobilizing mesenchymal stem cells to peripheral blood.